NurOwn® Platform
Progressive Multiple Sclerosis (MS)
Key Facts
About BrainStorm Cell Therapeutics
BrainStorm Cell Therapeutics is a clinical-stage biotechnology company singularly focused on defeating neurodegenerative diseases through its innovative NurOwn® autologous cellular therapy platform. Its most advanced program targets Amyotrophic Lateral Sclerosis (ALS), where it has secured a Special Protocol Assessment (SPA) with the FDA for a confirmatory Phase 3b trial following mixed but promising biomarker data from its prior Phase 3 study. The company's strategy hinges on validating NurOwn's multimodal mechanism of action in ALS to secure regulatory approval, while leveraging the platform's potential for expansion into other neurodegenerative indications with high unmet need.
View full company profileAbout BrainStorm Cell Therapeutics
BrainStorm Cell Therapeutics is a clinical-stage biotechnology company singularly focused on defeating neurodegenerative diseases through its innovative NurOwn® autologous cellular therapy platform. Its most advanced program targets Amyotrophic Lateral Sclerosis (ALS), where it has secured a Special Protocol Assessment (SPA) with the FDA for a confirmatory Phase 3b trial following mixed but promising biomarker data from its prior Phase 3 study. The company's strategy hinges on validating NurOwn's multimodal mechanism of action in ALS to secure regulatory approval, while leveraging the platform's potential for expansion into other neurodegenerative indications with high unmet need.
View full company profileTherapeutic Areas
Other Progressive Multiple Sclerosis (MS) Drugs
| Drug | Company | Phase |
|---|---|---|
| Masitinib | AB Science | Phase 3 |
| NG CELL | NeuroGenesis Bio | Phase 2 |